OraPharma Rolls Out MyARESTIN.com® Mobile After Successful Debut at ADA Annual Session

Mobile Version of Popular Website Puts Latest Periodontal Disease Diagnostic and Treatment Resources in the Hands of BlackBerry^®, iPhone^®, and DROID™ Users

Warminster, PA (October 18, 2010) − OraPharma, Inc., a specialty oral health company dedicated to bringing scientifically and technologically advanced products to the dental community, including ARESTIN^® (minocycline hydrochloride) Microspheres, 1 mg, will be rolling out the MyARESTIN.com^® Mobile site, after unveiling it at the recent ADA Annual Session in Orlando.

MyARESTIN.com^® Mobile is a convenient and portable personal practice resource that is derived from the popular website www.MyARESTIN.com. Like its website namesake, the mobile website is designed to help the entire dental team, including dentists, hygienists, and office managers, provide the highest level of periodontal patient care possible via the latest information delivered to virtually any smartphone.

According to Dina Weisleder, ARESTIN^® Product Director, “MyARESTIN.com^® Mobile was extremely well received when we demonstrated it during the ADA Annual Session. Plus, when you consider that 54% of dental professionals use smartphones such as the Apple^® iPhone^®, DROID^™, and BlackBerry^® Curve^™, and that 42% of them are using these devices to access dental information,¹ I’d say the dental industry is ready for MyARESTIN.com^® Mobile.”

Access to the mobile website is free, and will enable dental professionals to use their smartphones and mobile devices to access a wealth of periodontal disease information, including:

·         Retrieve general periodontal diagnostic and treatment guidelines

·         View or share an ARESTIN^® demonstration video

·         Review ARESTIN^® clinical data or prescribing information

·         Order ARESTIN^® for their patients

“MyARESTIN.com^® Mobile delivers the information dental professionals require to effectively treat periodontal disease whenever and wherever they need it,” explains Weisleder. “This includes the latest clinical information on the progression of periodontal disease, the proven efficacy and safety of ARESTIN^® as an adjunct to scaling and root planing (SRP),² effective patient communication tips, and the incorporation of periodontal treatment protocols. MyARESTIN.com^® Mobile puts this information at the fingertips of every dentist, hygienist, and office manager, via virtually any mobile device.”  

For the latest periodontal disease treatment information customized for your practice, and to take advantage of the immediacy and convenience of MyARESTIN.com^® Mobile, visit www.MyARESTIN.com with your browser-enabled mobile device.

About ARESTIN^®

ARESTIN^® (minocycline hydrochloride) Microspheres, 1 mg is indicated as an adjunct to scaling

and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN^® may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing.

ARESTIN^® contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.

The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.

References:

1.      Goodson JM, Gunsolley JC, Grossi SG, et al. Minocycline HCl microspheres reduce red-complex bacteria in periodontal disease therapy. J Periodontol. 2007;78 (8):1568-1579.

2.      Electronic survey, sponsored by OraPharma, Inc., of 62 dentists and registered dental hygienists attending the RDH Under One Roof Convention (Orlando, August 2010) and the American Dental Hygienists’ Association Annual Session (Las Vegas, June 2010).

About OraPharma, Inc.

OraPharma, Inc. is a specialty pharmaceutical company that discovers, develops, and commercializes therapeutics for the treatment of periodontal disease at various phases of progression. ARESTIN^® (minocycline hydrochloride) Microspheres, 1 mg (www.arestin.com) is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. For more information about OraPharma, Inc. and its products, visit www.orapharma.com.

oraPHARMA, INC.

ARESTIN^® is a registered trademark of OraPharma, Inc.

The third-party trademarks used herein are trademarks of their respective owners.

© OraPharma, Inc. 2010